PUBLICACIONES
GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
Pérez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, Manso L, Santaballa A, GonzalezMartin A.
Future Sci OA 2019;5(2): FSO370.
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
Romero I, Mallol P, Santaballa A, Del Campo JM, Mori M, González-Santiago S, Casado A, Vicente D, Ortega E, Herrero A, Guerra E, Barretina-Ginesta P, Rubio MJ, Martínez A, Bover I, Vidal L, Arcusa Á, Martín L, García Y, González-Martín A
Anticancer Drugs 2019;30(6):628-635.
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
Heitz F, Harter P, Åvall-Lundqvist E, Reuss A, Pautier P, Cormio G, Colombo N, Reinthaller A, Vergote I, Poveda A, Ottevanger PB, Hanker LC, Leminen A, Alexandre J, Canzler U, Sehouli J, Herrstedt J, Fiane B, Merger M, du Bois A
Gynecol Oncol 2019;152(2):235-242.
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
Garcia Garcia Y, de Juan Ferré A, Mendiola C, Barretina-Ginesta MP, Gaba Garcia L, Santaballa Bertrán A, Bover Barcelo I, Gil-Martin M, Manzano A, Rubio Pérez MJ, Romeo Marin M, Arqueros Núñez C, García-Martínez E, Gonzalez Martin A.
Int J Gynecol Cancer 2019;29(6):1050-1056.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators.
Lancet Oncol. 2017 Jul 25. pii: S1470-2045(17)30469-2. doi: 10.1016/S1470-2045(17)30469-2
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
A.Poveda, J.M. del Campo, I. Ray-Coquard, J. Alexandre, M. Provansal, E.M.Guerra Alía, A. Casado, A. Gonzalez-Martin, C. Fernández, I. Rodriguez, A. Soto, C. Kahatt, C. Fernandez Teruel, C.M. Galmarini, A. Pérez de la Haza, P. Bohan, D. Berton-Rigaud.
Annals of Oncology 2017; 28: 1280-1287. mdx111.doi:10.1093/annonc/mdx111.Published online 20 March 2017.
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR1, Monk BJ1, Herrstedt J1, Oza AM1, Mahner S1, Redondo A1, Fabbro M1, Ledermann JA1, Lorusso D1, Vergote I1, Ben-Baruch NE1, Marth C1, Mądry R1, Christensen RD1, Berek JS1, Dørum A1, Tinker AV1, du Bois A1, González-Martín A1, Follana P1, Benigno B1, Rosenberg P1, Gilbert L1, Rimel BJ1, Buscema J1, Balser JP1, Agarwal S1, Matulonis UA1; ENGOT-OV16/NOVA Investigators.
N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.
Independent radiologic review of AURELIA, a phase 3 trial of bevacizumab plus chemotherapy for platinum-resistant recurrent ovarian cancer.
Husain A, Wang Y, Hanker LC, Ojeda B, Anttila M, Breda E, Vuylsteke P, Pujade-Lauraine E.
Gynecol Oncol. 2016 Sep;142(3):465-70. doi: 10.1016/j.ygyno.2016.05.011. Epub 2016 Jun 25
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E.
Ann Oncol. 2016 Sep;27(9):1733-9. doi: 10.1093/annonc/mdw236. Epub 2016 Jun 10. PMID: 27287207
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
Brotto L, Brundage M, Hoskins P, Vergote I, Cervantes A, Casado HA, Poveda A, Eisenhauer E, Tu D; A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and Treatment of Cancer—Gynecologic Cancer Group (EORTC-GCG) and the Grupo de Investigación de Cáncer de Ovario (GEICO).
Support Care Cancer. 2015 Aug 25. [Epub ahead of print]
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, Pujade-Lauraine E.
J Clin Oncol. 2015 Aug 17. pii: JCO.2015.63.1408. [Epub ahead of print]
Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Bruixola G, Domingo S, Díaz R, Caballero J, Palomar L, De La Cueva H, Santaballa A.
Int J Gynecol Cancer. 2015 Feb;25(2):214-21. doi: 10.1097/IGC.0000000000000330.
Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.
Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, Ngan HY, Golfier F, Sekharan PK, Charry RC, Poveda A, Kim JW, Xiang Y, Berkowtiz R, Seckl MJ.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl3):S109-16. doi: 10.1097/IGC.0000000000000294. PMID: 25341573 [PubMed – in process]
Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.
Glasspool RM, González Martín A, Millan D, Lorusso D, Åvall-Lundqvist E, Hurteau JA, Davis A, Hilpert F, Kim JW, Alexandre J, Ledermann JA.
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S26-9. doi: 10.1097/IGC.0000000000000209. PMID: 25126954 [PubMed – in process]
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I.
J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17. Erratum in: J Clin Oncol. 2014 Dec 10;32(35):4025. PMID: 24637997 [PubMed – indexed for MEDLINE]
Updated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer).
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Oaknin A, Sneller V, Freudensprung U, Pignata S; OCTAVIA Investigators.
Eur J Cancer. 2014 Mar;50(4):862-3. doi: 10.1016/j.ejca.2013.12.001. Epub 2014 Jan 10. No abstract available. PMID: 24418723 [PubMed – indexed for MEDLINE]
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G, Kovalenko N, Oaknin A, Ronco JP, Freudensprung U, Pignata S; OCTAVIA Investigators.
Eur J Cancer. 2013 Dec;49(18):3831-8. doi: 10.1016/j.ejca.2013.08.002. Epub 2013 Sep 2. PMID: 24007819 [PubMed – indexed for MEDLINE]
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study.
Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J.
J Clin Oncol. 2013 Apr 20;31(12):1554-61. doi: 10.1200/JCO.2012.46.4057. Epub 2013 Mar 11.
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
González Martín A, Redondo A, Jurado M, De Juan A, Romero I, Bover I, Del Campo JM, Cervantes A, García Y, López-Guerrero JA, Mendiola C, Palacios J, Rubio MJ, Poveda Velasco A.
ClinTranslOncol. 2013 Mar 7. [Epub ahead of print]
Treatment of metastatic cervical cancer: future directions involving targeted agents
Diaz-Padilla I, Monk BJ, Mackay HJ, Oaknin A.
Crit Rev OncolHematol. 2013 Mar;85(3):303-14.
Bevacizumab as front-line treatment for newly diagnosed epithelial cancer
González Martín A, Bratos R, Márquez R, Alonso S, Chiva L.
ExpertRevAnticancerTher. 2013 Feb;13(2):123-9. doi: 10.1586/era.12.165.
Emerging concerns when evidence-based medicine is translated into real life: the case of neoadjuvant chemotherapy in ovarian cancer
González-Martín A, Chiva L.
CurrOncol Rep. 2013 Feb;15(1):4-6.
Ovarian low-grade serous carcinoma: a comprehensive update
Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershenson DM, Gonzalez-Martin A.
GynecolOncol. 2012 Aug;126(2):279-85. Epub 2012 Apr 30.
SEOM guidelines for cervical cancer
Oaknin A, Díaz de Corcuera I, Rodríguez-Freixinós V, Rivera F, del Campo JM.
Clin Transl Oncol. 2012 Jul;14(7):516-9.
SEOM guidelines for endometrial cancer
Oaknin A, Rodríguez-Freixinós V, Díaz de Corcuera I, Rivera F, del Campo JM.
Clin Transl Oncol. 2012 Jul;14(7):512-5.
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
Diaz-Padilla I, Duran I, Clarke BA, Oza AM.
Cancer Treat Rev. 2012 Oct;38(6):767-75. Epub 2012 Feb 29. Review.
Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls
Díaz-Padilla I, Razak AR, Minig L, Bernardini MQ, María Del Campo
J.Clin Transl Oncol. 2012 Jan;14(1):15-20.
Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review
Diaz-Padilla I, Amir E, Marsh S, Liu G, Mackay H.
Gynecol Oncol. 2012 Feb;124(2):354-65. Epub 2011 Nov 6.
Feasibility of a Modified Outpatient Regimen of Intravenous/Intraperitoneal Chemotherapy in Optimally Debulked Stage III Ovarian Cancer Patients: A GEICO Study
Oaknin A, Roda D, Gonzalez-Martin A, Chiva L, Garcia-Donas J, de Juan A, Redondo A, Martinez S, Garcia Y, Catot S, Ponce J, Del Campo JM, Cervantes A, Poveda A.
Int J Gynecol Cancer. 2011 Jul 1. [Epub ahead of print]
Current management of uterine sarcomas
García-Martínez E, Egea Prefasi L, García-Donas J, Escolar-Pérez PP, Pastor F, González-Martín A.
Clin Transl Oncol. 2011 May;13(5):307-14.
From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer
Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A.
Expert Opin Investig Drugs. 2011 May;20(5):591-4.
Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management
González Martín A.
Int J Gynecol Cancer. 2011 May;21(10 Suppl 1):S6-8.
Introduction. Trabectedin treatment in GYN cancers
Poveda A.
Int J Gynecol Cancer. 2011 May;21(10 Suppl 1):S1-2.
Early-stage ovarian cancer management: still a challenge
González Martín A.
Clin Transl Oncol. 2011 Feb;13(2):67-8. No abstract available.
Epothilones in the treatment of ovarian cancer
Diaz-Padilla I, Oza AM.
Future Oncol 2011 Apr; 7(4):559-68.
Brivanib alaninate in cancer
Diaz- Padilla, Siu LL.
Expert Opinion Investig Drugs 2011 Apr; 20(4): 577-586.
DNA repair-based mechanisms of platinum resistance in epithelial ovarian cancer. From bench to bedside
Diaz-Padilla I, Poveda A.
Clinical Ovarian Cancer 2010; 3:29-35.
Molecular characterization of ovarian cancer by gene-expression profiling
Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A.
Gynecol Oncol. 2010 Jul;118(1):88-92.
Epithelial ovarian carcinoma: current evidences and future perspectives in the first-line setting
González-Martín A, Toledo G, Chiva L.
Clin Transl Oncol 2010;12(6):418-30.
Angiogenesis and ovarian cancer
Gómez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D, Redondo A.
Clin Transl Oncol 2009;11(9):564-71.
Anti-angiogenic therapy in ovarian cancer: a great expectation to be confirmed
González Martín A.
Clin Transl Oncol 2009;11(9):559-60
The International Symposium on Advanced Ovarian Cancer
Poveda A, Vermorken JB.
Int J Gynecol Cancer. 2009;19 Suppl 2:S1
A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial
Ojeda Gonzalez B, Gonzalez Martin A, Bover Barcelo I, Fabregat i Mayol X, Mellado B, Rubio Perez MJ, Alonso Carrion L, Casado Herraez A, Calvo Garcia E, Churruca Galaz C, Arcusa Lanza A, Herrero Ibañez A, Adrover Cebrian E, Poveda Velasco A.
Am J Clin Oncol. 2008 Oct;31(5):481-7
Sparing fertility in young patients with endometrial cancer
Chiva L, Lapuente F, González-Cortijo L, Carballo N, García JF, Rojo A, Gonzalez-Martín A.
Gynecol Oncol 2008;111(2 Suppl):S101-4.
Multimodality treatment in locoregional gynecological cancer: cervical cancer treatment update
Poveda A, Gonzalez-Martin A.
Ann Oncol. 2008;19 Suppl 7:vii70-6.
Surgical treatment of recurrent cervical cancer: state of the art and new achievements
Chiva LM, Lapuente F, González-Cortijo L, González-Martín A, Rojo A, García JF, Carballo N.
Gynecol Oncol 2008;110(3 Suppl 2):S60-6.
The current role of neoadjuvant chemotherapy in the management of cervical carcinoma
González-Martín A, González-Cortijo L, Carballo N, Garcia JF, Lapuente F, Rojo A, Chiva LM.
Gynecol Oncol 2008;110(3 Suppl 2):S36-40.
Conservative management of patients with early endometrial carcinoma: a systematic review
Chiva de Agustín L, Lapuente Sastre F, Corraliza Galán V, Granados Galainena L, González Martín A, González Cortijo L, Carballo González N.
Clin Transl Oncol 2008;10(3):155-62.
Ten years of “Optimal Therapy in Advanced Ovarian Cancer. Update” meeting
Poveda A.
Int J Gynecol Cancer 2008;18 Suppl 1:67-70.
Human papillomavirus and cervical cancer prevention
A. Oaknin, P. Barretina.
Clin Transl Oncol 2008;10(12):804-11.
Actualización en cáncer ginecológico 2007: Cáncer de ovario y de cérvix
A. Poveda, A. Casado, MJ. Rubio, A. Oaknin, A. Santaballa, C. Mendiola, A. González, JM del Campo, J. Cueva, J. Casinello
Mfar, S.L. 2008
¿Cáncer de Cérvix? 100 preguntas más frecuentes
MJ. Rubio, A.Oaknin, A. Poveda
Edimsa, 2008
“25 preguntas más frecuentes en Oncología: Cáncer de Ovario”
A. Oaknin.
Publicaciones Permanyer 2008
Update in the management of ovarian and cervical cancer
A. Poveda, R. Salazar,J.M. Campo, C.Mendiola,J. Casinello, B. Ojeda, J.A.Arranz, A. Oaknin, J. García Foncillas, M.J. Rubio and A. González M
Clin Transl Oncol 2007;9(7):443-51
Intraperitoneal chemotherapy for optimally debulked advanced ovarian cancer: a new standard in patient care?
González Martín A.
Clin Transl Oncol 2007;9(7):409-11
Molecular biology of cervical cancer
González Martín A.
Clin Transl Oncol 2007;9(6):347-54
Treatment guidelines in ovarian cancer
Poveda Velasco A, Casado Herráez A, Cervantes Ruipérez A, Gallardo Rincón D, García García E, González Martín A, López García G, Mendiola Fernández C, Ojeda González B; GEICO Group.
Clin Transl Oncol 2007;9(5):308-16
Germ cell tumours of the ovary
Guillem V, Poveda A.
Clin Transl Oncol 2007;9(4):237-43
Randomized phase II trial of Carboplatin versus Paclitaxel and Carboplatin in platinum sensitive recurrent advanced ovarian carcinoma. A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study
Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balana C, Martinez E, Herrero A, Pardo B, Adrover E, Rifa J, Godes MJ, Moyano A, Cervantes A
Ann Oncol 2005;16:749-755
Gemcitabine in patients with ovarian cancer
Poveda A.
Cancer Treat Rev. 2005;31 Suppl 4:S29-37.
Ovarian cancer: is the news good enough?
Poveda A.
Int J Gynecol Cancer 2005;15 Suppl 3:298-306
Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy
González-Martín A; GEICO Group.
Int J Gynecol Cancer 2005;15 Suppl 3:241-6
Medical treatment of epithelial ovarian cancer
González-Martín AJ.
Expert Rev Anticancer Ther. 2004;4(6):1125-43.
Ovarian cancer treatment: what is new?
A. Poveda.
Int J Gynecol Cancer. 2003;13 Suppl 2:241-50.
Is combination chemotherapy superior to single-agent chemotherapy in second line treatment?
Gonzalez-Martin A; GEICO Group.
Int J Gynecol Cancer. 2003;13 Suppl 2:185-91.
Remarks and conclusions on ovarian cancer treatment
Poveda A.
Int J Gynecol Cancer 2001;11 Suppl 1:77-81
Advanced ovarian cancer: update, remarks and conclusions on optimal therapy
Poveda A.
Int J Gynecol Cancer 2000;10(S1):57-60.
Preface
Poveda A, Vermorken JB.
Int J Gynecol Cancer 2000;10(S1):1
Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer. A phase II trial of the Spanish Group for Ovarian Cancer
A.Cervantes, C.Mendiola, JM del Campo, B.Massuti, A.Casado, A.Escobedo, A.Moyano, B.Ojeda, A.Poveda and D.Benito.
Semin Oncol 1997;24 (5 Suppl 15):S15-40-S15-43.
